PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Download Poster (1.35 MB)

Publication

EULAR •
14 June, 2025 •
•

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

Kenneth Saag , Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Hyon Choi

Available materials

Poster

Publication

EULAR •
14 June, 2025 •
•

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Kevin Byram, Herman Mann, Danielle Hammond, Sinisa Savic, Yohei Kirino , Carmelo Gurnari, Mael Heiblig, Thibault Comont, Arsene Mekinian, Mrinal Patnaik, Lachelle D. Weeks, Gary Ho, Onima Chowdhury, Adam Al-Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin-Lavialle, Peter Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster, David B. Beck

Available materials

Poster

Publication

EULAR •
13 June, 2025 •
•

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

Lachelle D. Weeks, Danielle Hammond, Sinisa Savic, Mael Heiblig, Onima Chowdhury, Arsene Mekinian, Carmelo Gurnari, Radhakrishnan Ramchandren, Sophie Georgin-Lavialle, Marcela A. Ferrada, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, David B. Beck, Matthew J. Koster

Available materials

Poster

Publication

ACR •
29 October, 2025 •
•